Skip to main content

Abstract

The goal of any anti-cancer therapy is to eradicate malignant cells and prevent their regrowth. The extent of cell kill is dependent upon the sensitivity of the cells and the dose of cytotoxic therapy administered. For many treatment modalities the dose limiting factor is myelosuppression. Hence, it is often impossible to give the maximum desired dose since patients would succumb to bone marrow aplasia and associated complications such as hemorrhage and infection. This problem can be ameliorated by the infusion of marrow following cytotoxic therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Bortin MM, Rimm AA (1989) Increasing utilization of bone marrow transplantation. Transplantation 48:453–458

    Article  PubMed  CAS  Google Scholar 

  • Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds) (1990) Graft-vs-host disease: Immunology, pathophysiology, and treatment. New York: Marcel Dekker, Inc. 1–725

    Google Scholar 

  • O’Reilly RJ (1991) Marrow transplantation as a model system for correction of genetic disease. In: Lindsten J, Pettersson U, (eds), Etiology of Human Disease at the DNA Level, London: Raven Press, Ltd. 261–289

    Google Scholar 

  • Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn J-Y, Colombat P, Goldstone AH, Gorin NC, Flesh M, Laporte J-P, Maraninchi D, Pico J, Bosly A, Anderson C, Shots R, Biron P, Cabanillas F, Dicke K (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med 316:1493

    Article  PubMed  CAS  Google Scholar 

  • Santos GW (1983) History of bone marrow transplantation. Clin Haematol 12:611–639

    PubMed  CAS  Google Scholar 

  • Storb R. Bone marrow transplantation. In: Roitt IM, Delves PJ, (eds), Encyclopedia of Immunology, London: W.B. Saunders, Co. (in press)

    Google Scholar 

  • Thomas ED (1990) Bone marrow transplantation — past, present and future. In: The Nobel Prizes, Stockholm: The Nobel Foundation

    Google Scholar 

  • Thomas ED, Storb R, Clift RA, Fefer A, Johnson RL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD (1975) Bone-marrow transplantation. N Engl J Med 292:832–843; 895–902

    Article  PubMed  CAS  Google Scholar 

  • van Bekkum DW, De Vries MJ (1967) Radiation Chimeras, London: Logos Press Ltd.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Deeg, H.J., Klingemann, HG., Phillips, G.L. (1992). Introduction. In: A Guide to Bone Marrow Transplantation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-97374-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-97374-1_1

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-97376-5

  • Online ISBN: 978-3-642-97374-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics